Nirogacestat hydrobromide

Nirogacestat Hydrobromide is the hydrobromide salt form of nirogacestat, a selective gamma secretase (GS) inhibitor with antitumor activity. Upon administration, nirogacestat targets and binds to GS, thereby blocking the proteolytic activation of Notch receptors. This inhibits the Notch signaling pathway and results in the induction of apoptosis in tumor cells that overexpress Notch. The integral membrane protein GS is a multi-subunit protease complex that cleaves single-pass transmembrane proteins, including Notch receptors, at residues within their transmembrane domains. Overexpression of the Notch signaling pathway has been correlated with increased tumor cell growth and survival. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Ogsiveo and nirogacestat HBr. Its PubChem CID is 121513889.

CAS No 1962925-29-6
Molecular Formula C27H43Br2F2N5O
Molecular Weight 651.5 g/mol
Synonyms (2S)-2-[[(2S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-N-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide;dihydrobromide

Frequently Asked Questions